Who are Vehicle to Oxymetazoline HCL Cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epinephrine Injection, Brompheniramine + pseudoephedrine, Lumify®, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, Experimental dosing of labetalol, Norepinephrine (dynamic group).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vehicle-to-oxymetazoline-hcl-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Vehicle to Oxymetazoline HCL Cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vehicle to Oxymetazoline HCL Cream (Vehicle to Oxymetazoline HCL Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist. Area: Dermatology.

phase 3 Alpha-1 adrenergic agonist Alpha-1 adrenergic receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Vehicle to Oxymetazoline HCL Cream (Vehicle to Oxymetazoline HCL Cream) — Allergan. Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vehicle to Oxymetazoline HCL Cream TARGET	Vehicle to Oxymetazoline HCL Cream	Allergan	phase 3	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Brompheniramine + pseudoephedrine	Brompheniramine + pseudoephedrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)
Lumify®	Lumify®	Bausch & Lomb Incorporated	marketed	Alpha-1 adrenergic receptor agonist	Alpha-1 adrenergic receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Experimental dosing of labetalol	Experimental dosing of labetalol	Albany Medical College	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Norepinephrine (dynamic group)	Norepinephrine (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist class)

Allergan · 2 drugs in this class
EMS · 1 drug in this class
Institute of Liver and Biliary Sciences, India · 1 drug in this class
Medical University of Graz · 1 drug in this class
Rawalpindi Medical College · 1 drug in this class
Tehran Heart Center · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vehicle to Oxymetazoline HCL Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/vehicle-to-oxymetazoline-hcl-cream. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab